6831-50-1 Usage
Chemical Class
Oxazole
Physical State
Yellow crystalline solid
Application
Used in organic synthesis
Potential applications in the pharmaceutical industry
Used as a building block for synthesizing other organic compounds
Importance
Valuable tool for researchers and scientists in organic chemistry and drug discovery
Specific Features
Contains a chloro group (2-chloro-3,4-dimethoxybenzylidene)
Contains methoxy groups (3,4-dimethoxybenzylidene)
Contains a phenyl group (2-phenyl-1,3-oxazol-5(4H)-one)
Role in Drug Development
Potential for developing new drugs and pharmaceutical products
Utility
Offers versatility in chemical transformations due to its structure
Potential Impact
Contributes to advancements in medicinal chemistry and pharmacology
Research Significance
Stimulates exploration of novel synthetic routes and pharmacological activities
Check Digit Verification of cas no
The CAS Registry Mumber 6831-50-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,8,3 and 1 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6831-50:
(6*6)+(5*8)+(4*3)+(3*1)+(2*5)+(1*0)=101
101 % 10 = 1
So 6831-50-1 is a valid CAS Registry Number.
6831-50-1Relevant articles and documents
Antileshmanial activities of synthetic substituted 2-phenyl-4-[phenylmethylidene]-1,3-oxazol-5(4H)-ones
Khan, Saadia Razi,Ghouri, Nida,Karim, Aneela,Naz, Farzana,Fakhri, Muhammad Imran,Perveen, Shahnaz,Khan, Khalid Mohammed,Taha, Muhammad,Choudhary, Muhammad Iqbal
, p. 980 - 985 (2016/01/12)
Substituted 2-phenyl-4-[phenylmethylidene]-1,3-oxazol-5(4H)-ones 1-27 were evaluated for their activity against Leishmania major. Compounds 1-27 demonstrated in vitro antileishmanial activities with IC50 values between 28.9 - 69.05 μM, as compared to standard drug pentamidine (IC50 = 5.09 ± 0.04 μM). Compounds 12 (IC50 = 28.90 ± 1.10 μM), 24 (IC50 = 31.4 ± 2.15 μM), 13 (IC50 = 35.0 ± 3.18 μM), 16 (IC50 = 35.0 ± 3.13 μM), and 25 (IC50 = 35.0 ± 3.18μM) displayed signifiant antileishmanial activities. Whereas, compounds 8-10, 15, 19, and 26 with IC50 values of 62.2 ± 3.36, 57.8 ± 2.30, 57.72 ± 5.02, 56.18 ± 4.40, 57.85 ± 2.25, 69.05 ± 6.20, 54.8 ± 1.50, and 57.8 ± 2.30 μM showed a moderate antileishmanial activities.